The neonatal Fc receptor (FcRn) plays a crucial role in maintaining IgG homeostasis by binding to immunoglobulins in a pH-dependent manner. This receptor not only recycles IgG, thereby extending its ...

Please provide your email address to receive an email when new articles are posted on . Blood dendritic cell antigen 2 and neonatal fragment crystallizable receptor are two novel strategies in lupus ...

The FDA approved rozanolixizumab-noli (Rystiggo), a neonatal Fc receptor blocker, to treat adults with generalized myasthenia gravis (gMG), UCB announced Tuesday. The drug is the first approved to ...

Please provide your email address to receive an email when new articles are posted on . Patients with Sjögren’s disease treated with nipocalimab, a novel neonatal Fc receptor blocker, demonstrate ...

Nipocalimab's FDA approval revolutionizes generalized myasthenia gravis treatment, offering rapid symptom relief and improved patient outcomes across diverse populations. Farmakidis explains how ...

A data monitoring committee recommended stopping the phase 3 trials of efgartigimod in thyroid eye disease due to lack of efficacy.

The engineering and functional characterization of the Fc domain are key to therapeutic antibodies’ efficacy, safety, and pharmacokinetics. The Fc domain is responsible for mediating interactions with ...